1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Network Pharmacology Analysis of Xuanfei Baidu Granule in the Treatment of Intestinal Flora Disorder

      1 , 2 , 3 , 4 , 4 , 5 , 6
      Advanced Gut & Microbiome Research
      Hindawi Limited

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective. This study is aimed at analyzing the molecular mechanism of Xuanfei Baidu Granule (XFBDG) in the treatment of intestinal flora disorder based on network pharmacology. Methods. The TCMSP database was used to obtain the active components and target proteins of XFBDG, while the GeneCards database was used to obtain the related proteins of intestinal flora disorder. The Rx64 4.0.2 software was used to analyze the GO functional enrichment and KEGG pathway enrichment of drug component target protein and disease-related protein to obtain the pathway-enriched proteins and screen the core proteins for topology analysis of the pathway target by using the STRING database and Cytoscape v3.8.2 software. The Cytoscape v3.8.2 software was used to analyze the relationship between each component and enriched protein, and the AutoDock Vina software was used for molecular docking of core proteins and components. Results. XFBDG contains 133 active components that can act on 249 proteins related to intestinal flora disorder. The effects include the following: (i) regulation of functions—the response to drug, cellular response to chemical stress, response to oxidative stress, and RNA polymerase II-specific DNA-binding transcription factor binding and (ii) regulation of signaling pathways such as the IL-17 signaling pathway, TNF signaling pathway, and Th17 cell differentiation pathway. The enriched core proteins in these pathways are IFNG, IL4, PTGS2, JUN, and IL1B that set in a higher level of binding with the corresponding drug components. Conclusion. XFBDG can act on IFNG, IL4, PTGS2, JUN, and IL1B proteins through its active components such as quercetin, luteolin, and kaempferol to regulate the IL-17, TNF, and Th17 cell differentiation pathways and further regulate the response to drug, cellular response to chemical stress, response to oxidative stress, and RNA polymerase II-specific DNA-binding transcription factor binding. In addition, owing to its antioxidant and anti-inflammatory properties and related immune responses, XFBDG can achieve a balance of intestinal flora and microbial metabolism.

          Related collections

          Most cited references26

          • Record: found
          • Abstract: found
          • Article: not found

          Lead- and drug-like compounds: the rule-of-five revolution.

          Citations in CAS SciFinder to the rule-of-five (RO5) publication will exceed 1000 by year-end 2004. Trends in the RO5 literature explosion that can be discerned are the further definitions of drug-like. This topic is explored in terms of drug-like physicochemical features, drug-like structural features, a comparison of drug-like and non-drug-like in drug discovery and a discussion of how drug-like features relate to clinical success. Physicochemical features of CNS drugs and features related to CNS blood-brain transporter affinity are briefly reviewed. Recent literature on features of non-oral drugs is reviewed and how features of lead-like compounds differ from those of drug-like compounds is discussed. Most recently, partly driven by NIH roadmap initiatives, considerations have arisen as to what tool-like means in the search for chemical tools to probe biology space. All these topics frame the scope of this short review/perspective.: © 2004 Elsevier Ltd . All rights reserved.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome.

            Sepsis and the acute respiratory distress syndrome (ARDS) are major causes of mortality without targeted therapies. Although many experimental and clinical observations have implicated gut microbiota in the pathogenesis of these diseases, culture-based studies have failed to demonstrate translocation of bacteria to the lungs in critically ill patients. Here, we report culture-independent evidence that the lung microbiome is enriched with gut bacteria both in a murine model of sepsis and in humans with established ARDS. Following experimental sepsis, lung communities were dominated by viable gut-associated bacteria. Ecological analysis identified the lower gastrointestinal tract, rather than the upper respiratory tract, as the likely source community of post-sepsis lung bacteria. In bronchoalveolar lavage fluid from humans with ARDS, gut-specific bacteria (Bacteroides spp.) were common and abundant, undetected by culture and correlated with the intensity of systemic inflammation. Alveolar TNF-α, a key mediator of alveolar inflammation in ARDS, was significantly correlated with altered lung microbiota. Our results demonstrate that the lung microbiome is enriched with gut-associated bacteria in sepsis and ARDS, potentially representing a shared mechanism of pathogenesis in these common and lethal diseases.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Autophagy and inflammation in chronic respiratory disease

              Persistent inflammation within the respiratory tract underlies the pathogenesis of numerous chronic pulmonary diseases including chronic obstructive pulmonary disease, asthma and pulmonary fibrosis. Chronic inflammation in the lung may arise from a combination of genetic susceptibility and environmental influences, including exposure to microbes, particles from the atmosphere, irritants, pollutants, allergens, and toxic molecules. To this end, an immediate, strong, and highly regulated inflammatory defense mechanism is needed for the successful maintenance of homeostasis within the respiratory system. Macroautophagy/autophagy plays an essential role in the inflammatory response of the lung to infection and stress. At baseline, autophagy may be critical for inhibiting spontaneous pulmonary inflammation and fundamental for the response of pulmonary leukocytes to infection; however, when not regulated, persistent or inefficient autophagy may be detrimental to lung epithelial cells, promoting lung injury. This perspective will discuss the role of autophagy in driving and regulating inflammatory responses of the lung in chronic lung diseases with a focus on potential avenues for therapeutic targeting. Abbreviations AR allergic rhinitis AM alveolar macrophage ATG autophagy-related CF cystic fibrosis CFTR cystic fibrosis transmembrane conductance regulator COPD chronic obstructive pulmonary disease CS cigarette smoke CSE cigarette smoke extract DC dendritic cell IH intermittent hypoxia IPF idiopathic pulmonary fibrosis ILD interstitial lung disease MAP1LC3B microtubule associated protein 1 light chain 3 beta MTB Mycobacterium tuberculosis MTOR mechanistic target of rapamycin kinase NET neutrophil extracellular traps OSA obstructive sleep apnea PAH pulmonary arterial hypertension PH pulmonary hypertension ROS reactive oxygen species TGFB1 transforming growth factor beta 1 TNF tumor necrosis factor
                Bookmark

                Author and article information

                Contributors
                Journal
                Advanced Gut & Microbiome Research
                Advanced Gut & Microbiome Research
                Hindawi Limited
                2755-1652
                October 11 2022
                October 11 2022
                : 2022
                : 1-13
                Affiliations
                [1 ]Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, 300250 Tianjin, China
                [2 ]State Key Laboratory of Component-Based Chinese, Tianjin University of Traditional Chinese Medicine, 301617 Tianjin, China
                [3 ]School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 301617 Tianjin, China
                [4 ]First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China
                [5 ]Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
                [6 ]Haihe Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
                Article
                10.1155/2022/7883756
                94d75957-a1cd-4c1c-b191-c1e550e6088c
                © 2022

                https://creativecommons.org/licenses/by/4.0/

                History

                Comments

                Comment on this article